Copay Accumulator Programs & Pharma: What’s Next?

A closer look at CAPs and how they might affect your brand

Dynamics between pharma and the market-based healthcare sector it serves have invariably been complex, with one of the biggest drivers of that complexity being effective management of patient demand and payer systems.

And over time, payer business models are becoming increasingly convoluted. The newest stratagem in this push and pull is the copay accumulator program, or CAP. First introduced in 2018, these programs are now rapidly being rolled out by payers, with data showing that nearly one-third of commercially insured patients are now directly impacted by CAPs – enrolled either in plans that have implemented copay accumulator adjustment or closely-related copay maximizers.

The CAP, with its differing and confusing scopes of application, is one more contour to successfully navigate when attempting to balance clinical and economic value in product development and commercialization decisions.

What is a CAP?

Copay accumulator programs (CAPs) permit employers and PBMs to exclude copay assistance from the calculation of a patient’s annual deductible, effectively negating the value of the copay assistance for said patient.

Prior to the introduction of the CAP, payers sought to guide patients toward less expensive treatments by making them pay a higher portion of a drug’s costs. Drug-makers responded by increasing the financial aid they offer, in the form of copay assistance, to shield consumers from these rising expenses. Payers, however, have now turned the tables on Pharma. They are using CAPs to leverage the value of the manufacturer copay coupon, in turn increasing beneficiary cost-sharing amounts to meet deductible amounts.

Deallus Copay Accumulator Programs Pharma White Paper
DOWNLOAD WHITE PAPER

You may also be interested in…

Revolutionizing Blood Cancer Treatment: A Dive into Cutting-Edge Therapies

World Blood Cancer Day [28 May 2024] serves as a stark reminder of the significant challenges faced by the millions battling these life-threatening diseases. Here at Deallus, we have been privileged enough to partner with many leading companies in this space to support the development of lifechanging therapies across haemato-oncology.

The need for innovation in Women’s Health

Women’s Health Week (14-20 May 2024) provides an opportunity to reflect on the changing landscape for the access, treatment, and representation of women across healthcare. We’re proud that many of the clients we are partnering with are part of driving much needed change and reform within Women’s Health, lending our experience and expertise to the innovation that is required.

A message from our Chairwoman

At Deallus we are fortunate to have Ulrike Meier as our Chairwoman since 2020. Ulrike has written a brilliant blog reflecting on her time with Deallus so far and shares some insights into, even if removed from daily business, as Chairwoman, there is room to make a difference. From being authentic, focusing on the bigger picture, to providing motivation and guidance, Ulrike explores what key elements she prioritises in her role and how we can all play a part in organisation success.

To learn more about this topic, or to find out about ways in which Deallus can help you, please get in touch.

For any questions or comments on this thought piece, please reach out to Julie Munch Khan – Deallus Chief Commercial Officer

Julie Munch Khan – Deallus Chief Commercial Officer